Discover investment opportunities in Top 100 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 100 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 100 Stocks Under $2 using our Smart AI Filter.
7 stocks found for "Top 100 Stocks Under $2"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.44 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±88.4% Price volatility | -5.2 Valuation | 0.00% Annual yield | |||
0.88 Risk measure | ±63.0% Price volatility | -95.7 Valuation | 0.00% Annual yield | |||
0.66 Risk measure | ±97.4% Price volatility | -0.5 Valuation | 0.00% Annual yield | |||
1.47 Risk measure | ±57.7% Price volatility | 113.3 Valuation | 0.00% Annual yield | |||
1.46 Risk measure | ±85.2% Price volatility | -0.9 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes QNCX an intriguing option for small-cap investors?
A: QNCX, as a development-stage biotech company, appeals to investors seeking high growth potential driven by innovative drug development. Biotech stocks like QNCX can make substantial gains if successful in trials, though they come with significant risk due to regulatory and market uncertainties.
Q: How do geopolitical factors affect URG's stock performance?
A: URG operates in uranium mining, affected by shifts in nuclear energy policies and geopolitical tensions. Governmental support for nuclear energy and changes in trade agreements can influence demand and prices, impacting URG's revenue and stock performance.
Q: Why might investors consider OVID for a diversified portfolio?
A: OVID Pharmaceuticals focuses on developing treatments for rare neurological diseases, providing diversification through exposure to the biotech sector. While promising high returns, biotech stocks like OVID carry high risk due to clinical trial dependencies.
Q: Does IMUX offer opportunities for growth-focused investors?
A: IMUX, or Immunic, Inc., works on immune modulating therapies, appealing to growth investors who target biotech breakthrough potentials. Success in clinical trials could spur significant stock appreciation, though with inherent risks of drug approval processes.
Q: What are the potential risks associated with investing in MREO?
A: MREO, a clinical-stage biopharma company, faces risks related to drug pipeline uncertainties, regulatory approvals, and potential capital needs for ongoing research. Biotech stocks like MREO can experience high volatility due to these factors.
Q: How might SDST perform in an economic downturn?
A: SDST's performance during economic downturns is influenced by its industry sector. If it operates in consumer staples or essential services, it might exhibit resilience. However, lack of specific data on SDST's sector necessitates further research.
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read more